RecruitingPHASE1, PHASE2NCT04785196
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Studying Liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ascentage Pharma Group Inc.
- Principal Investigator
- Ye Guo, MD, PhDShanghai East Hospital
- Intervention
- APG-115(drug)
- Enrollment
- 95 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (3)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
- Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai, China
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04785196 on ClinicalTrials.govOther trials for Liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07377747Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaAustralia and New Zealand Sarcoma Association
- RECRUITINGNCT06436846Genomic Risk in Retroperitoneal SarcomaFox Chase Cancer Center
- RECRUITINGNCT04699292International Prospective Registry on Local Treatment Approaches in MLSThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04557449Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPfizer
- ACTIVE NOT RECRUITINGPHASE2NCT04438824Palbociclib and INCMGA00012 in People With Advanced LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT03361436Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryOHSU Knight Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryM.D. Anderson Cancer Center